Core Viewpoint - Genetron Holdings Limited is holding an extraordinary general meeting to vote on a proposed merger that would take the company private and terminate its listing on NASDAQ [1][2][3] Group 1: Merger Details - The merger involves Genetron Holdings Limited merging with New Genetron Holding Limited and Genetron New Co Limited, resulting in Genetron becoming a wholly-owned subsidiary of Parent [2] - If the merger is completed, Genetron's American depositary shares (ADSs) will no longer be traded on any stock exchange, and the ADS program will be terminated [2] - The board of directors has unanimously recommended that shareholders vote in favor of the merger agreement and related transactions [3] Group 2: Meeting Information - The extraordinary general meeting is scheduled for February 21, 2024, at 9:00 a.m. Beijing time, and shareholders of record as of February 9, 2024, will be entitled to vote [1][3] - ADS holders must instruct The Bank of New York Mellon to vote on their behalf by January 22, 2024 [3] Group 3: Company Overview - Genetron Holdings Limited is a leading precision oncology platform in China, specializing in molecular profiling tests, early cancer screening products, and companion diagnostics [1][6] - The company utilizes advanced technologies in molecular biology and data science to enhance cancer treatment and has developed a comprehensive oncology portfolio [6][7]

Table of Contents | --- | --- | --- | --- | --- | |--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Genetron Holdings Limited (NASDAQ:GTH) Q1 2022 Earnings Conference Call June 2, 2022 8:30 AM ET Company Participants Evan Xu - Chief Financial Officer Sizhen Wang - Co-Founder, Chairman & Chief Executive Officer Conference Call Participants Yang Huang - Credit Suisse Operator Good morning, and thank you for standing by. Welcome to the First Quarter 2022 Genetron Health Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a questi ...

Table of Contents | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------- ...

Genetron Holdings Limited (NASDAQ:GTH) Q4 2021 Earnings Conference Call March 29, 2022 8:30 AM ET Company Participants Hoki Luk - Head of Investor Relations Sizhen Wang - Chief Executive Officer and Chairman of the Board Yun-Fu Hu - Chief Medical Officer Evan Ce Xu - Chief Financial Officer Hai Yan - Chief Technology Officer Yuchen Jiao - Chief Technology Officer Conference Call Participants Sung Ji Nam - BTIG Yang Huang - Credit Suisse Operator Good day and thank you for standing by. Welcome to the Fourth ...

[Genetron Health Announces Changes to the Board of Directors and Executive Officer](index=2&type=section&id=Genetron%20Health%20Announces%20Changes%20to%20the%20Board%20of%20Directors%20and%20Executive%20Officer) [Board of Directors Changes](index=2&type=section&id=Board%20of%20Directors%20Changes) Genetron Health announced the appointment of Dr. Chao Tang and Mr. Shan Fu as new Directors, replacing Dr. Weiwu He and Mr. Weidong Liu who resigned for personal reasons, with co-founder Mr. Sizhen Wang appointed as the new Chairman and Dr. Weiwu He named Chairman Emeritus Summary of Board of Directors Changes | Role Change | Individual | Details | | :--- | :--- | :--- | | **Appointment** | Dr. Chao Tang | Appointed as Director | | **Appointment** | Mr. Shan Fu | Appointed as Director | | **Appointment** | Mr. Sizhen Wang | Appointed as new Chairman of the Board | | **Resignation** | Dr. Weiwu He | Resigned as Chairman of the Board; appointed Chairman Emeritus | | **Resignation** | Mr. Weidong Liu | Resigned as Director | - The company believes the new appointments will strengthen Genetron, citing Dr. Tang's expertise in interdisciplinary sciences and Mr. Fu's corporate board and global healthcare industry experience[4](index=4&type=chunk) [Executive Officer Change](index=2&type=section&id=Executive%20Officer%20Change) Effective June 30, 2021, Mr. Kevin Ying Hong will resign as Chief Operating Officer (COO) for personal reasons, transitioning to the role of Senior Advisor to continue contributing his expertise to the company - Mr. Kevin Ying Hong will resign as COO for personal reasons, effective June 30, 2021, and will become a Senior Advisor to Genetron Health[4](index=4&type=chunk) [Biographies of New Directors](index=2&type=section&id=Biographies%20of%20New%20Directors) The new directors bring extensive experience from academia and the global healthcare industry, with Dr. Chao Tang specializing in physics and systems biology and Mr. Shan Fu in corporate finance and investment within the healthcare sector [Dr. Chao Tang](index=2&type=section&id=Dr.%20Chao%20Tang) - Dr. Chao Tang is a Chair Professor of Physics and Systems Biology at Peking University, a Fellow of the American Physical Society, and an Academician of the Chinese Academy of Sciences, focusing his research on the interface between physics and biology[5](index=5&type=chunk) [Mr. Shan Fu](index=3&type=section&id=Mr.%20Shan%20Fu) - Mr. Shan Fu has served as joint CEO of Vivo Capital LLC since October 2013 and previously was the Chief Representative of China at Blackstone Group, also serving as a Non-Executive Director for several other publicly listed healthcare companies, including TOT BIOPHARM, InnoCare Pharma, and Sinovac Biotech[6](index=6&type=chunk) [Safe Harbor Statement](index=3&type=section&id=Safe%20Harbor%20Statement) - The announcement contains forward-looking statements as defined by the U.S. Private Securities Litigation Reform Act of 1995, which involve inherent risks and uncertainties, and the company cautions that actual results could differ materially from those projected without undertaking any duty to update this information[7](index=7&type=chunk)